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MicroRNAs (miRNAs) govern an expanding number
of biological and disease processes. Understanding
the mechanisms by which the miRNA pathway is
regulated, therefore, represents an important area
of investigation. We determined that the human
miRNA-generating complex is comprised of Dicer
and phospho-TRBP isoforms. Phosphorylation of
TRBP is mediated by the mitogen-activated protein
kinase (MAPK) Erk. Expression of phospho-mimic
TRBP and TRBP phosphorylation enhanced miRNA
production by increasing stability of the miRNA-
generating complex. Mitogenic signaling in response
to serum and the tumor promoter PMA was depen-
dent on TRBP phosphorylation. These effects were
accompanied by a coordinated increase in levels of
growth-promoting miRNA and reduced expression
of let-7 tumor suppressor miRNA. Conversely, phar-
macological inhibition of MAPK/Erk resulted in an
anti-growth miRNA profile. Taken together, these
studies indicate that the MAPK/Erk pathway regu-
lates the miRNA machinery and suggest a general
principle, wherein signaling systems target the
miRNA pathway to achieve biological responses.
INTRODUCTION
miRNAs are 22 nucleotide cellular RNAs that target mRNAs
to regulate protein expression. miRNAs are derived from
genome-encoded primary transcripts that are processed to
65 nucleotide stem-loop precursor (pre-) miRNAs by a pro-
cessing complex comprised of the ribonuclease III Drosha and
double-strand RNA-binding protein (dsRBP) DGCR8/Pasha
(Lee et al., 2003; Denli et al., 2004; Gregory et al., 2004; Han
et al., 2004). Exportin-5/Ran-GTP translocates pre-miRNA
from nucleus to cytoplasm where they serve as substrates for
the miRNA-generating machinery (Yi et al., 2003; Lund et al.,
2004). The miRNA-generating complex consists of the ribonu-
clease III Dicer (Bernstein et al., 2001; Hutvagner et al., 2001;
Lee et al., 2004; Zhang et al., 2004) and a partner dsRBP (Liu112 Cell 139, 112–122, October 2, 2009 ª2009 Elsevier Inc.et al., 2003; Forstemann et al., 2005; Jiang et al., 2005; Saito
et al., 2005). In humans, Dicer is accompanied by the HIV TAR
RNA-binding protein (TRBP; Chendrimada et al., 2005; Haase
et al., 2005; Lee et al., 2006). Mature miRNAs direct sequence-
specific silencing of target transcripts through Argonaute-con-
taining effector complexes by means that are dependent and
independent of mRNA stability (Filipowicz et al., 2008).
The importance of the miRNA pathway in mammalian biology
was first highlighted through genetic studies. Chromosomal
ablation of the RNaseIII catalytic domain of murine Dicer resulted
in stem cell depletion and embryonic lethality (Bernstein et al.,
2003). Independent targeting of Dicer and DGCR8/Pasha alleles
in murine embryonic stem cells resulted in deficiencies in centro-
meric silencing and differentiation (Kanellopoulou et al., 2005;
Wang et al., 2007). Related approaches further established
the importance of Dicer and partner dsRBPs in murine and
Drosophila germline stem cell division andmaintenance (Hatfield
et al., 2005; Murchison et al., 2007; Park et al., 2007) and zygotic
development (Tang et al., 2007).
Identification of the first miRNA and its biological target
preceded the discovery of the miRNAmachinery. TheC. elegans
lin-4 locus, and encoding miRNA, was found to direct develop-
mental timing through recognition of homologous repeat
elements within the lin-14 30-untranslated region (UTR; Lee
et al., 1993; Wightman et al., 1993). Subsequent work revealed
that lin-4 and the highly evolutionarily conserved let-7 miRNA
govern a network of regulatory factors in directing temporal
development (Reinhart et al., 2000). Recent studies have demon-
strated the necessity of numerous other miRNAs in organismal
development.
Aberrant expression of developmental genes is often related to
disease etiology including cancer. Determination of let-7-medi-
ated regulation of let-60/Ras in C. elegans development led to
anobserved inversecorrelationbetween let-7andRasexpression
in normal and human lung tumor tissue (Johnson et al., 2005).
30UTR engineering to mimic chromosomal translocations found
in some human tumors revealed let-7-mediated silencing of
high-mobility group A2-mediated oncogenic transformation
(Mayr et al., 2007). Oligonucleotide-mediated inhibition of let-7
enhanced lung cancer cell proliferation, and let-7 overexpression
inhibited cell division (Johnson et al., 2007; Yu et al., 2007). These
and other studies (He et al., 2007; Tavazoie et al., 2008) provided
cleardemonstrationofmiRNAs functioningas tumor suppressors.
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Figure 1. The Human miRNA-Generating
Complex Contains Dicer and Phospho-
TRBP Isoforms
(A) Purification scheme of the miRNA-generating
complex from HeLa cytoplasmic (S100) extract.
Numbers indicate salt (NaCl) concentration (mM).
(B) Correlation of the miRNA-generating activity
peak with Dicer and TRBP immunoblots following
hydroxyapatite column fractionation.
(C) Coomassie-stained polyacrylamide gel illus-
trating the difference in banding pattern between
recombinant TRBP produced in bacteria and
insect cells.
(D) Insect-cell-produced recombinant TRBP was
subjected to phosphatase (PPase) treatment alone
or in combination with phosphatase inhibitors.
(E) Heparin and hydroxyapatite column fractions
of HeLa extract were subjected to phosphatase
treatment and immunoblotting performed with
anti-TRBPantibody. Nonphosphorylated recombi-
nant (rec) TRBP was run as a marker.
(F) Schematic domain structure of TRBP with
arrows indicating the positions of four phospho-
serine residues identified by mass spectrometry.
Shaded boxes represent annotated double-strand
RNA-binding domains (dsRBD).
(G) HeLa cells were transfected with constructs
encoding Flag-tagged wild-type (WT) or phos-
pho-mutant TRBP bearing serine-to-alanine (SDA)
mutations at the four phospho-residues identified.
Immunoblotting was performed with anti-Flag
antibody.miRNAs have also been found to promote oncogenesis.
Elevated expression of the miR-17-92 ‘‘oncomir’’ cluster was
found in hematopoietic, colorectal, and lung cancers and trans-
genic expression of this polycistron promoted cancer cell growth
(Ota et al., 2004; He et al., 2005; Hayashita et al., 2005). Through
miRNA microarray profiling and a forward genetic screen
miR-10b, miR-373, and miR-520c were found to initiate tumor
cell invasion and metastasis (Ma et al., 2007; Huang et al.,
2008). Thus, miRNAs appear to share a paradigm similar to
that of protein (proto-) oncogenes and tumor suppressors in
regulating developmental and cancer biology (Hanahan and
Weinberg, 2000; Pardal et al., 2005).
In addition to those outlined above, there is growing under-
standing of the importance of miRNAs in regulating a spectrum
of biological and pathophysiological processes. Among these
are cardiopathology (van Rooij et al., 2006), neurodegeneration
(Bilen et al., 2006), skeletal muscle hypertrophy (Clop et al.,
2006), viral pathogenicity (Triboulet et al., 2007), and innate (Ped-
ersen et al., 2007) and adaptive immunity (Koralov et al., 2008).
These and numerous other studies outlining the role of miRNAs
as key biological regulators raise important questions as to how
the miRNA pathway is regulated. Moreover, there is an enor-
mous void in our understanding of the relationship between the
miRNApathway and other cell signaling pathways. In the presentstudy, we identify MAPK/Erk-mediated phosphorylation of the
human miRNA-generating complex and demonstrate the impor-
tance of this regulation in effecting mitogenic signaling. This
concept may be a general principle, wherein a myriad of sig-
naling pathways target the miRNA machinery to achieve biolog-
ical responses.
RESULTS
The Human miRNA-Generating Complex Consists
of Dicer and Phospho-TRBP Isoforms
We used sequential chromatography to isolate the human
miRNA-generating complex from HeLa cytoplasmic extract
(Figure 1A). Throughout the purification process, peak miRNA-
generating activity cofractionated with Dicer and TRBP (Fig-
ure 1B). Further, reconstitution studies demonstrated that both
Dicer and TRBP are required for efficient interaction with pre-
miRNA substrate and miRNA production (Figure S1 available
online).
Purified miRNA-generating fractions immunoblotted for TRBP
revealed a multiple banding pattern (Figure 1B) similar to that
observed by others (Chendrimada et al., 2005; Haase et al.,
2005; Lee et al., 2006). Recombinant TRBP produced in bacteria
yielded a single product of the expected size (Figure 1C). InCell 139, 112–122, October 2, 2009 ª2009 Elsevier Inc. 113
contrast, recombinant TRBP generated in an insect cell (eukary-
otic) expression system exhibited a multiple banding pattern,
suggesting the possibility of posttranslational modifications.
Treatment of insect-cell-produced TRBP with phosphatase re-
sulted in a collapse of this multiple banding pattern, whereas
cotreatment with phosphatase and phosphatase inhibitors abro-
gated this effect (Figure 1D). Similarly, phosphatase treatment of
purified HeLa fractions also resulted in a collapsed TRBP band-
ing pattern (Figure 1E). Mass spectrometry analysis identified
four phospho-serine residues (Figure 1F and Table S1). Authen-
ticity of the identified sites was validated by the different banding
profiles between wild-type (WT) and serine-to-alanine mutant
TRBP expressed in human cells (Figure 1G). The number of sites
mutated inversely correlated with the number of isoforms de-
tected (not shown), indicating that all four identified sites were
important in producing phospho-isoforms. Collectively, these
results indicate that the human miRNA-generating complex
consists of Dicer and phospho-TRBP isoforms.
TRBPPhosphorylation Stabilizes themiRNA-Generating
Complex
To investigate functionality of TRBP phosphorylation, we gener-
ated isogenic cell lines expressing WT, phospho-mutant (serine-
to-alanine (SDA)), and phospho-mimic (serine-to-aspartate
(SDD)) TRBP. We employed a Flipase (Flp)/Flp recognition target
(FRT) site-directed recombination system to achieve single copy
integration at the same genomic locus driven by the same
promoter. As expected, these isogenic cell lines expressed
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Figure 2. Expression of Phospho-Mimic
TRBP Enhances Stability of the miRNA-
Generating Complex
(A) Quantitative RT-PCR analysis of trbp (solid
bars) and dicer (light bars) mRNA relative to b-actin
from isogenic Flp-In 293 cells expressingwild-type
(WT), phospho-mutant (SDA) and phospho-mimic
(SDD) TRBP. Values represent means ± standard
deviation (SD), n = 3.
(B) Immunoblots of Dicer and TRBP from isogenic
Flp-In 293 cells expressing WT, SDA, and SDD
TRBP. Multiple bands for WT TRBP in 293 cells
are visualized with longer exposure.
(C) Quantitative analysis of TRBP (solid bars) and
Dicer (light bars) expression. * indicates greater
than WT and SDA. # indicates greater than SDA
(p < 0.05). Values represent means ± SD, n = 3.
(D) Cells were treated with cyclohexamide for 2, 4,
or 6 hr to determine stability of WT, SDA, and SDD
TRBP.
(E) Quantitative analysis of protein decay (t1/2:
SDA (squares) 1.7 ± 0.2 hr,WT (circles) 3.0 ± 0.1 hr,
and SDD (triangles) >6 hr]. * indicates SDD greater
than WT and SDA (p < 0.02). Values represent
means ± standard deviation (SD), n = 3.
similar levels of dicer and trbp mRNA
(Figure 2A). However, immunoblot anal-
ysis revealed higher expression of the
phospho-mimic relative to WT and phos-
pho-mutant proteins (Figures 2B and 2C).
Expression of phospho-mimic TRBP also increased Dicer
expression relative to that for WT and phospho-mutant TRBP
(Figures 2B and 2C). These findings are consistent with previous
reports of interdependent expression between RNaseIII
enzymes and partner dsRBPs (Liu et al., 2003; Chendrimada
et al., 2005; Haase et al., 2005; Jiang et al., 2005; Lee et al.,
2006; Park et al., 2007; Han et al., 2009).
These differences in protein levels suggested that phospho-
mimic TRBP may be more stable than WT and phospho-mutant
TRBP. To test this hypothesis, cells were treated with the trans-
lation inhibitor cyclohexamide and protein decay wasmonitored.
As shown in Figures 2D and 2E, phospho-mutant TRBP had the
shortest half-life (1.7 ± 0.2 hr), followed by WT (3.0 ± 0.1 hr) and
phospho-mimic (>6 hr; p < 0.015). Taken together, these findings
indicate that expression of phospho-mimic TRBP enhances
stability of the miRNA-generating complex.
Consistent with elevated levels of Dicer and TRBP, phospho-
mimic TRBP-expressing cells demonstrated higher in vitro
miRNA-generating activity compared to WT and phospho-mu-
tant (Figure 3A). miRNA-generating complex formation assays
indicated a higher capacity to interact with pre-miRNA substrate
in phospho-mimic compared with WT and phospho-mutant
TRBP-expressing cells (Figure S2). Recombinant WT and
phospho-mimic TRBP yielded similar effects in reconstituting
miRNA-generating activity in vitro (Figure S3). Thus, although
phosphorylation state may alter some intrinsic property of the
miRNA-generating enzyme, stabilization and elevated expres-
sion of Dicer-TRBP is a principal cause for increased miRNA114 Cell 139, 112–122, October 2, 2009 ª2009 Elsevier Inc.
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Figure 3. Expression of Phospho-Mimic
TRBP Enhances miRNA Production and
miRNA-Mediated Target Silencing
(A) In vitro miRNA-generating assays were per-
formed with 15 mg of extracts prepared from
isogenic Flp-In 293 cells expressing WT, SDA,
and SDD TRBP. * indicates greater than WT and
SDA. # indicates greater than SDA (p < 0.04).
Values represent means ± SD, n = 3.
(B) Cells were cotransfected with plasmids ex-
pressing pre-miR-21 or pre-miR-30, Renilla lucif-
erase to normalize and firefly luciferase encoding
eight miR-30 target sites in the 30UTR.
(C) miR-30 production was assessed by northern
blot (left) and quantified (middle). U6 RNA was
used as a loading control. miR-30-mediated si-
lencing was measured by the ratio of firefly to
Renilla luciferase activity and expressed as per-
cent silencing relative to pre-miR-21 control (right).
* indicates greater than WT and SDA (p < 0.01).
Values represent means ± SD, n = 4.production in phospho-mimic TRBP-expressing cells. Expres-
sion of phospho-mimic TRBP also resulted in greater cellular
production of miRNA relative to that forWT and phospho-mutant
(Figure 3C). To determine if the observed differences in miRNA
production impacted downstream miRNA function, miRNA-
mediated silencing assays were conducted using a reporter
construct under the control of miR-30 (Yi et al., 2003). In line
with a higher level of miR-30 production, phospho-mimic TRBP-
expressing cells exhibited greater miR-30-mediated silencing
relative to WT and phospho-mutant (Figures 3B and 3C). These
results were consistent for all miRNAs tested including miR-21,
miR-133, and miR-206 (Figure S4). Collectively, these findings
suggest that phosphorylation of TRBP enhances stability of
the miRNA-generating complex, resulting in enhanced miRNA
production and miRNA-mediated target silencing.
The miRNA-Generating Complex Is a Target
of the MAPK/Erk Pathway
To identify kinases that phosphorylate TRBP, we performed
computational analysis (Huang et al., 2005) of phospho-TRBP
peptides (Table S1). This analysis indicated potential MAPK
substrate sequences. Coimmunoprecipitation studies using
cells stably expressing Flag-TRBP demonstrated cellular inter-
action between TRBP and phospho(p)-Erk1/2 (Figure 4A).
Next, we developed an in vitro TRBP phosphorylation assay
using recombinant TRBP generated in E. coli as substrate and
HeLa cell extract as source material for kinase activity. Peak
TRBP phosphorylation activity corresponded with pErk2
following Superdex 200 column fractionation (Figure 4B).
Activation of MAPKs such as Erk requires phosphorylation by
an upstream kinase known as a MAPK kinase (MKK). Constitu-
tively active mutant MKK1 (MKK1*; DN3 [deleted residues
32–51], S218D, S222D] is commonly used to specifically activateErk1/2 (Mansour et al., 1994; Khokhlatchev et al., 1997). Re-
combinant MKK1* and Erk2 were both required to reconstitute
in vitro TRBP phosphorylation (Figure 4C).
To determine the role of MKK1/Erk in modifying cellular TRBP,
we treated cells stably expressing Flag-TRBP with the mitogen
and tumor promoter phorbol 12-myristate 13-acetate (PMA).
PMA-induced activation of pErk1/2 resulted in phosphorylation
and accumulation of TRBP (Figure 4D). Pretreatment of cells
with the MKK1 inhibitor U0126 attenuated PMA-induced phos-
phorylation of TRBP, whereas pretreatment with the MKK3/
p38 inhibitor SB203580 did not. Moreover, cellular expression
of MKK1* resulted in phosphorylation and accumulation of
TRBP (Figure 4E). Collectively, these studies indicate that
TRBP is a target of the MKK1/Erk pathway.
Concomitant with MKK1*-induced phosphorylation of TRBP
was an accumulation of TRBP and Dicer proteins (Figures 5A
and 5C, top). Such changes occurred without any increase in
trbp or dicer transcript levels (not shown). These findings parallel
those of the aforementioned studies involving expression of
phospho-mimic TRBP (Figure 2) and indicate that phosphoryla-
tion of TRBP stabilizes the miRNA-generating complex.
Functionally, MKK1*-induced phosphorylation of TRBP re-
sulted in elevated production of miRNA and enhanced miRNA-
mediated silencing (Figures 5B and 5C). To determine if the
MKK1*-mediated enhancement of miRNA pathway activity was
dependent on phosphorylation of TRBP, parallel studies were
performed using cells stably expressing phospho-mutant
TRBP. Despite activation of pErk1/2, expression of MKK1* in
these cells did not result in changes in TRBP or Dicer expression,
miRNA production, or miRNA-mediated silencing (Figures 5A–
5C). The basis for dominance of transgenic TRBP is depicted
in Figure S5. Column fractionation of cell extracts derived
from cells stably expressing transgenic TRBP revealed thatCell 139, 112–122, October 2, 2009 ª2009 Elsevier Inc. 115
miRNA-generating activity exhibited perfect correlation with
Dicer and transgenic TRBP. Thus, in these cells, the miRNA-
generating enzyme is comprised mostly of Dicer and transgenic
TRBP. In this way, phosphorylation of background WT TRBP in
phospho-mutant TRBP-expressing cells would not be expected
to influence miRNA production. Taken together, these findings
demonstrate that the MKK1/Erk pathway enhances the capacity
of the miRNA pathway via phosphorylation of TRBP.
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Figure 4. TRBP Is Phosphorylated by MAPK/Erk
(A) HeLa cell extracts from cells stably expressing Flag-TRBP were immunoprecipitated using anti-GFP or anti-Flag antibodies. Western blots (WB) were
performed using anti-phospho(p)-Erk1/2 antibody.
(B) Correlation of in vitro TRBP phosphorylation activity and pErk2 following Superdex 200 fractionation of HeLa cell extract.
(C) In vitro reconstitution of TRBP phosphorylation activity using constitutively active recombinant MKK1 (rMKK1*) and recombinant Erk2 (rErk2).
(D) HeLa cells stably expressing Flag-TRBPwere serum-starved for 24 hr, treated with DMSO, U0126, or SB203580 for 1 hr, followed by PMA treatment for 24 hr.
(E) HeLa cells stably expressing Flag-TRBP were transfected with an empty vector or one encoding MKK1*.A
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Figure 5. Activation of MKK1/Erk Enhances miRNA Pathway Activity in a Phospho-TRBP-Dependent Manner
(A) HeLa cells stably expressing WT or SDA TRBP were transfected with an empty vector or one encoding MKK1*. Immunoblots were performed for pErk1/2,
Dicer, TRBP, and actin.
(B) miR-30 northern blots were performed to compare the level of miR-30 production following cotransfection of either empty vector or MKK1* and pre-miR-30
plasmid. U6 RNA was used as a loading control.
(C) Quantitative representation of Dicer expression (top), miR-30 expression (middle), and miR-30-mediated silencing (bottom) as described in Figure 3B.
* indicates MKK1* (light bars) greater than empty vector (black bars; p < 0.02). Values represent means ± SD, n = 4.116 Cell 139, 112–122, October 2, 2009 ª2009 Elsevier Inc.
The miRNA-Generating Complex Is an Effector
of the MAPK/Erk Pathway
Having established regulation of miRNA expression via MAPK/
Erk-mediated phosphorylation of TRBP, we wanted to determine
the effect of TRBP modification on global miRNA expression.
We conducted miRNA microarray studies of phospho-mutant
and phospho-mimic TRBP-expressing cells. Consistent with the
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Figure 6. Cells Expressing Phospho-Mimic TRBP Exhibit a Pro-
Growth miRNA Expression Profile and Higher Levels of Cellular
Growth and Serum-Restricted Survival
(A) Regression analysis of miRNA microarray studies from Flp-In 293 cells ex-
pressing SDA and SDD TRBP. The dotted line represents equivalent miRNA
levels between cell lines. Data points above the dotted line (64.6% of data
points) indicate higher miRNA expression in SDD versus SDA TRBP-express-
ing cells. Data points below the dotted line (35.4%) indicate lower expression
in SDD compared with SDA TRBP-expressing cells. The equation of the
non-let-7 (closed circles) regression line is y = 1.22x  93.5 with a correlation
coefficient of 0.96 (p < 0.0001). The let-7 family of miRNA (let-7a, b, c, d, e, f, g;
open circles) demonstrated the opposite pattern of expression. The equation
of the let-7 regression line is y = 0.52x + 1202.2 with a correlation coefficient of
0.95 (p < 0.002). Data are means of three independent analyses for each cell
line. For simplicity, error bars are not shown (but see Table S2).
(B) miRNA quantitative PCR was performed to assess expression of miR-17,
miR-20a, miR-92a, and let-7a. * indicates differences in expression between
HeLa cells stably expressing SDA (black bars) versus SDD TRBP (light bars;
p < 0.03; n = 3). Values represent means ± SD.
(C) HeLa cells were incubated in serum-free media overnight and cultured in
media containing 0%, 0.2%, 1.0%, and 10% serum for 48 hr. Cell counts at
48 hr were normalized to those at 0 hr. * indicates cells stably expressing
SDD TRBP (light bars) that demonstrated greater cell populations relative to
those expressing SDA TRBP (black bars; p < 0.02; n = 3). Values represent
means ± SD.findings from the above-mentioned experiments employing
expressed miRNA, phospho-mimic TRBP-expressing cells ex-
hibited higher miRNA levels relative to phospho-mutant (Fig-
ure 6A). Given the importance of the MAPK/Erk pathway in
mediating cell growth and proliferation, we were particularly inter-
ested inmiRNAs that havebeendemonstrated to function in these
processes.Among themiRNAs thatwereupregulated inphospho-
mimic TRBP-expressing cells were growth-promoting miR-17,
miR-20a, and miR-92a. Interestingly, there was one very notable
exception to this pattern. Levels of the let-7 tumor suppressor
miRNA family were lower in phospho-mimic compared to phos-
pho-mutant TRBP-expressing cells (Figure 6A). These results
suggested a mitogenic miRNA profile including a coordinated
upregulation of pro-growth miRNAs and downregulation of anti-
growth miRNAs in response to phosphorylation of TRBP.
To validate thesemicroarray data and to trackmiRNA changes
in subsequent experiments, we used miRNA northern blot
hybridization and miRNA quantitative RT-PCR to examine ex-
pression of growth-promoting miR-17, miR-20a, and miR-92a
and growth-suppressing let-7a. These studies confirmed that
expression of phospho-mimic TRBP resulted in higher levels of
pro-growth miR-17, miR-20a, and miR-92a and lower levels of
let-7a tumor suppressor miRNA relative to phospho-mutant
(Figures 6B and S6A). Quantitative RT-PCR for pri-let-7a
(Figure S7) and miRNA northern blot analyses (Figure S6A) indi-
cated that these changes were mediated posttranscriptionally.
The let-7miRNA family continues to demonstrate unique charac-
teristics. For example, the stem cell marker Lin28 specifically
regulates let-7 biogenesis (Heo et al., 2008; Newman et al.,
2008; Viswanathan et al., 2008) and distinct let-7 ribonucleopro-
tein complexes have been identified in C. elegans (Chan et al.,
2008). Thus, TRBP phosphorylation may influence Lin28 activity
or let-7 RISC turnover or may alter the interface between pre-
let-7 and the miRNA-generating enzyme. Although the under-
lying mechanisms for differential regulation of let-7 in response
to expression of phospho-mimic TRBP are not known, there is
clear logic in coordinating levels of pro- and anti-growth miRNA.
Given the growth promoting miRNA profile of phospho-mimic
TRBP expressing cells, we wanted to determine whether these
cells exhibited any differences in growth characteristics. Indeed,
phospho-mimic TRBP expressing cells exhibited higher levels
of expansion relative to phospho-mutant (Figure 6C, 1% and
10% serum). Under serum-restricted conditions, phospho-
mimic TRBP-expressing cells also demonstrated enhanced
cell viability relative to phospho-mutant (Figure 6C, 0% and
0.2% serum). These growth and survival differences were
observed for all media conditions tested. However, the magni-
tude of this disparity was inversely related to serum concentra-
tion. We reasoned that in the presence of high levels of serum,
miRNA expression represents one of a myriad of mitogenic
signals. As serum levels are progressively restricted, these other
inputs are attenuated and the role of the miRNA machinery in
regulating cell signaling becomesmore pronounced. These find-
ings suggest that phosphorylation of TRBP is important in medi-
ating the hallmarks of MAPK/Erk signaling including proliferation
and cell survival (Anjum and Blenis, 2008).
As a key stimulus for MAPK/Erk, we wanted to determine if
phosphorylation state of TRBP could be perturbed throughCell 139, 112–122, October 2, 2009 ª2009 Elsevier Inc. 117
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Figure 7. Phosphorylation of TRBP Mediates MAPK/Erk Signaling
(A) Immunoblots from cells stably expressing WT and SDA TRBP incubated in
media containing 0% or 10% serum.
(B) Serum-induced changes in miRNA expression in WT (black bars) and SDA
(light bars) TRBP-expressing cells. Cells were washed with PBS twice and
incubated in 0% or 10% serum for 48 hr. Data are presented as percent
change relative to serum-free levels where * indicates WT changes greater
than those for SDA (p < 0.01; n = 4). Values represent means ± SD.
(C) Cells expressing WT and SDA TRBP were washed with PBS twice, incu-
bated in serum-free media overnight, and plated in media containing 10%
serum for 48 hr. Cell growth is expressed relative to cell count at 0 hr. * indi-
cates p < 0.001 (n = 3). Values represent means ± SD.
(D) PMA-induced changes in miRNA expression in cells stably expressing WT
(black bars) and SDA (light bars) TRBP. Data are percent change relative to
DMSO treatment where * indicates p < 0.05 (n = 4). Values represent
means ± SD.
(E) Cells stably expressingWT or SDA TRBPwere cultured in serum-freemedia
overnight and seeded in serum-free media containing DMSO or PMA, and cell
populationswere counted after 24 hr. * indicates that PMA treatment (light bars)
resulted in greater cell viability relative to DMSO (black bars; p < 0.001).
** indicates that PMA treatment yielded greater cell counts for WT versus
SDA TRBP-expressing cells (p < 0.01; n = 3). Values represent means ± SD.
(F) HeLa cells were treated with DMSO or U0126 for 48 hr. Data are expressed
as percent change relative to DMSO (n = 4). All data shown are at the level of
p < 0.05. Values represent means ± SD.118 Cell 139, 112–122, October 2, 2009 ª2009 Elsevier Inc.serum. Consistent with the effects of MKK1* expression, activa-
tion of pErk1/2 with serum stimulation resulted in phosphoryla-
tion and accumulation of TRBP (Figure 7A). In line with the effects
of phospho-mimic TRBP expression, serum-induced TRBP
phosphorylation increased expression of pro-growth miRNA
and decreased expression of let-7a growth suppressor miRNA
(Figure 7B). These serum-induced changes were largely attenu-
ated in phospho-mutant TRBP-expressing cells. To determine if
serum-induced mitogenic signaling was dependent on phos-
phorylation of TRBP, WT and phospho-mutant TRBP-express-
ing cells were cultured in serum-free media overnight followed
by serum exposure for 48 hr. Cells expressing phospho-mutant
TRBP demonstrated a 25% growth disadvantage relative to
WT (Figure 7C). These findings indicate that serum-induced
mitogenic signaling is, at least in part, phospho-TRBP depen-
dent.
We performed similar studies using another mitogen. PMA-
induced phosphorylation of TRBP (Figure 4D) resulted in a
pro-growth miRNA profile including an upregulation of growth-
promoting miRNA and a decrease in let-7a growth-suppressor
miRNA in WT but not phospho-mutant TRBP-expressing cells
(Figure 7D). PMA treatment enhanced cell survival during serum
starvation in both WT and phospho-mutant TRBP-expressing
cells (Figure 7E). However, the magnitude of this effect was
greater for WT than for phospho-mutant TRBP-expressing cells.
Similar to findings with serum stimulation, these findings indicate
that the mitogenic effects of PMA are partially mediated through
phosphorylation of TRBP. Taken together, these results indicate
that phosphorylation of TRBP is important in effecting cellular
proliferation and serum-restricted survival.
As expression of phospho-mimic TRBP, serum stimulation,
and PMA treatment resulted in a coordinated pro-growth miRNA
profile, we sought to determine if pharmacological inhibition of
the MAPK/Erk pathway would yield a reciprocal anti-growth
miRNA response. Indeed, treatment of cells with the MKK1/2
inhibitor U0126 resulted in downregulation of pro-growth miR-
17, miR-20a, and miR-92a and an increase in let-7a miRNA
tumor suppressor expression (Figures 7F and S6B). As MKK1
inhibitors are currently being assessed in clinical oncology trials,
we tested six cancer cell lines to determine the generality of this
pharmacological response. Human cervical (HeLa), gastric (Ka-
toIII), and lung carcinoma (A549) cells exhibited this coordinated
anti-growth miRNA expression pattern, and mammary adeno-
carcinoma (MDA MB231) and glioblastoma (T97G) cells pro-
duced a decrease in growth-promoting miRNA following U0126
treatment (Figure S8). Of the six cancer cell lines evaluated, only
one osteosarcoma cell line (U2OS) did not demonstrate changes
in the miRNAs examined. These findings indicate a concerted
miRNA regulatory program capable of responding positively in
response to mitogenic signals and negatively following inhibition
of these signals. Collectively, these data indicate that the MAPK/
Erk pathway targets the human miRNA-generating complex to
effect cell signaling.
DISCUSSION
Our understanding of the importance of miRNA in regulating
development, homeostasis, and pathophysiology continues to
expand. Therefore, elucidating the mechanisms by which the
miRNA pathway is governed represents a critical area of investi-
gation. A key component of these endeavors is understanding
the inter-relationship between the miRNA machinery and other
cellular systems. The present study indicates that the miRNA-
generating complex is regulated by MAPK/Erk and that this
regulation is important in effecting mitogenic signaling. To our
knowledge, the current work provides the first demonstration
of a direct connection between a cell signaling pathway and
the core miRNA machinery and suggests that other cellular
networks also target the miRNA pathway to carry out functional
cellular responses.
The principle of miRNA pathway regulation is in its infancy.
Clearly, transcriptional control is important. Two protein factors
have been shown to modulate expression of specific miRNAs
through posttranscriptional mechanisms. Lin28 has been shown
to modulate pri-let-7 and pre-let-7 processing (Heo et al., 2008;
Newman et al., 2008; Viswanathan et al., 2008). Smad transcrip-
tional transducers have been shown to facilitate pri-miR-21 pro-
cessing in mediating transforming growth factor b stimulation
(Davis et al., 2008). Prolyl hydroxylation has been shown to
govern stability of Argonaute2 and siRNA-mediated silencing
(Qi et al., 2008). An autoregulatory feedback loop regulating
expression of the microprocessing complex has been outlined
(Han et al., 2009). Dead End 1 has been demonstrated to modu-
late interactions between the miRNA silencing machinery and
target mRNA (Kedde et al., 2007). The present work introduces
new principles in understanding miRNA regulatory mechanisms.
Genetic studies of the miRNA machinery and, later, of specific
miRNAs have been instrumental in elucidating the importance
of miRNA in biology. Here, we utilize the study of posttransla-
tional modification to identify upstream signaling-mediated
regulation of the miRNA machinery and demonstrate that this
governance is important in effecting downstream cellular sig-
naling. It is likely that other cellular systems similarly target the
miRNA pathway in order to achieve biological responses.
The major function of the MAPK/Erk pathway is to appropri-
ately respond to cellular signals with respect to cellular growth,
survival, proliferation, and differentiation (Roux and Blenis,
2004). Although these processes are tightly connected, specific
events for each have been identified (Bonni et al., 1999; Chen
et al., 2008). Effectors of the MAPK/Erk pathway include media-
tors of the transcriptional and translational apparatus (Anjum and
Blenis, 2008). That serum stimulation resulted in reduced cellular
expansion in phospho-mutant TRBP-expressing cells relative
to WT indicates that cellular proliferation is mediated, in part,
through phosphorylation of the miRNA-generating complex.
Further, that PMA preferentially enhanced serum-restricted cell
viability in WT relative to phospho-mutant TRBP-expressing
cells demonstrates that phosphorylation of the miRNA-gener-
ating complex is also important for cell survival signaling. Thus,
in addition to regulating transcription and translation, MAPK/
Erk also acts on the miRNA-generating complex to effect mito-
genic signaling. Interestingly, a recent report identified a tran-
scriptional connection between the Raf/MAPK/Erk pathway
and miRNA expression (Dangi-Garimella et al., 2009). The lin28
locus was identified as a transcriptional target of c-Myc pro-
viding a means through which Raf signaling can modulateexpression of let-7. This study and the current work suggest
that the Raf/MAPK/Erk cascademay regulatemiRNA expression
through parallel mechanisms.
The loss of balance between activities of oncogenes and
tumor suppressors is a key occurrence in neoplastic progression
(Hanahan and Weinberg, 2000; Pardal et al., 2005). Expression
of phospho-mimic TRBP and mitogenic stimuli produced a
concerted upregulation of miRNAs that have previously been
demonstrated to promote tumor progression and downregula-
tion of growth-retarding miRNA. A reciprocal anti-growth miRNA
profile was observed in response to pharmacological inhibition
of MAPK/Erk. These findings suggest a bidirectional miRNA-
generating logic that corresponds with and/or directs cellular
behavior. Therefore, a potential mechanism of action of MAPK
inhibitors, including those in clinical development, may be
through targeting of the miRNA machinery. Moreover, there is
widespread interest in the development of miRNA-based
therapeutics. Numerous groups have reported the potential of
miRNAmimics and anti-miRNA oligonucleotides to drive desired
outcomes in preclinical studies. Though advances in oligonucle-
otide drug development have been made, significant challenges
remain. That a small molecule compound produced targeted
and coordinated reprogramming of miRNA expression indi-
cates that miRNA-based therapeutic interventions need not rely
solely on oligonucleotide drug development. Purposeful miRNA
changes may be achievable through traditional pharmacological
approaches.
Elucidating the signaling systems, including identification of
modifications, modified targets, and modifiers, represents an
important direction in understanding regulation of the miRNA
pathway. Moreover, determining the requirement of these post-
translational controls in producing functional cellular responses
will advance understanding of these signaling systems. Just as
other genomic regulatory mechanisms such as transcription,
splicing, pre-mRNA processing, and export can be modulated
through signaling-induced modifications, the micro-RNA appa-
ratus appears to demonstrate similar tunability. The current
work establishes a direct connection between a cell signaling
pathway and the core miRNA machinery. These studies indicate
that the MAPK/Erk pathway regulates the miRNA-generating
complex and that this regulation is important in effecting mito-
genic signaling.
EXPERIMENTAL PROCEDURES
General Procedures
Flag, His, and pErk antibodies were purchased from Sigma. Actin and Dicer
antibodies were obtained from Abcam. TRBP antiserum was raised against
purified full-length recombinant TRBP. Phosphatase was obtained from
NEB. Phosphatase inhibitor treatment included 10 mM sodium fluoride
(Sigma), 4 mM sodium orthovanadate (Sigma), and 4 mM b-glycerophosphate
(Calbiochem). Serine-to-alanine (SDA) phospho-mutant and serine-to-aspar-
tate (SDD) phospho-mimic TRBP were constructed by the ‘‘QuikChange’’
system (Stratagene). Immunoprecipitation was performed using Protein A
agarose from Santa Cruz Biotechnology.
Cell Culture Procedures
Transfections were performed using Lipofectamine 2000 (Invitrogen). Cyclo-
hexamide (Sigma) treatment was performed using 100 mg/ml. U0126 (Prom-
ega) was used at a concentration of 20 mM and PMA (Sigma) was used atCell 139, 112–122, October 2, 2009 ª2009 Elsevier Inc. 119
100 ng/ml. Unless otherwise stated, cell treatments were administered for
a duration of 48 hr with amedia change, including fresh dosage of compounds,
after 24 hr. Cell populations were assayed using a Cell Titer Glo luminescent
cell viability assay (Promega). Typically, cells were cultured in serum-free
media overnight and plated the following day at a density of 1000 cells/
96-well in experimental media. Cell counts were taken at 48 hr and normalized
to those obtained at 0 hr.
Two sets of stable cell lines were employed in the current work. Isogenic cell
lines expressing WT, phospho-mutant, and phospho-mimic His-TRBP were
produced using a Flipase (Flp)/Flp recognition target site-directed recombina-
tion system (Invitrogen). Briefly, Flp-In 293 cells (Invitrogen) were cotrans-
fected with pcDNA5/FRT containing TRBP cDNA and Flp recombinase. Stable
clones were selected using 200 mg/ml hygromycin. HeLa cells stably express-
ing (Flag)3-TRBP were generated from a modified pCI-neo vector encoding
WT, phospho-mutant, or phospho-mimic TRBP. Clones were selected using
500 mg/ml G418.
mRNA and miRNA Analysis
Northern blots were performed as previously reported (Park et al., 2007).
Probe sequenceswere as follows: miR-30—gcugcaaacauccgacugaaag; U6—
gcaggggccatgctaatcttctctgtatcg. mRNA and miRNA RT-quantitative PCR
studies were carried out using Taqman assay systems (Applied Biosystems)
where mRNA expression was normalized to b-actin and miRNA expression
was normalized to RNU44. miRNA microarray analysis was conducted by
LC Sciences. The platform database used was Sanger miR Base 10.0.
Least-squares linear regression analysis was performed with Sigma Plot
10.0. p values were obtained with the corresponding F statistic derived from
the analysis of variance for each regression.
miRNA-Mediated Silencing
Cells were transfected with constructs encoding pre-miR-21 (control) or pre-
miR-30, firefly luciferase under the control of eightmiR-30 target sites encoded
in the 30UTR and Renilla luciferase to normalize results (Yi et al., 2003).
Reporter activity was assayed using a Dual Luciferase Reporter System
(Promega). Pre-miR-30-mediated silencing was determined by the ratio of
firefly to Renilla luciferase activity and expressed as percent silencing relative
to pre-miR-21 control.
Statistical Analysis
Experiments were run in duplicate or triplicate and repeated in a minimum of
three independent trials. Image quantitation was performed using Scion Image
analysis software (NIH). Data are represented as means ± standard deviation
(SD). Two-tailed t tests were employed where the minimum level of signifi-
cance was p < 0.05.
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